[Controlled trial of Cymbi on efficacy and tolerance (author's transl)].
Ampicillin (Cymbi -Dolorgiet) was administered in various administration forms to 139 patients with acute and chronic infections of the urinary tract, biliary tract and other infections for an average of 10 days under conditions similar to those of general practice. In a controlled investigation the efficacy and tolerance were examined, and in parallel studies the in vitro activities were correlated with the blood levels obtainable in vivo to determine the therapeutic value in the treated group. The chemotherapeutic efficacy was high and the tolerance was good. The incidence of side effects was relatively low. Only 3;5% of the patients showed unfavorable results or had to stop the treatment.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001660:Biliary Tract Diseases / Q000188:drug therapy; D002214:Capsules; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004304:Dosage Forms; D004342:Drug Hypersensitivity; D005260:Female; D005750:Gastric Juice; D006801:Humans; D066298:In Vitro Techniques; D007239:Infections / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012995:Solubility; D012996:Solutions; D013607:Tablets; D014552:Urinary Tract Infections / Q000188:drug therapy
D002214:Capsules; D004304:Dosage Forms; D012996:Solutions; D013607:Tablets; D000667:Ampicillin
Kontrollierte Prüfung von Cymbi auf Effektivität und Verträglichkeit